Insufficient Mitigation of Bone Loss by Zoledronic Acid after Treatment with Denosumab

참고문헌 (12)

1. Tarun Kadaru, "Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year", 대한골대사학회지, 28(1), pp.51~58 (2021), 대한골대사학회
2. A. Modi, "Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years", Osteoporosis International, 28(4), pp.1355~1363 (2017), Springer Science and Business Media LLC[DOI]
3. Henry G. Bone, "Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass", The Journal of Clinical Endocrinology & Metabolism, 96(4), pp.972~980 (2011), The Endocrine Society[DOI]
4. M. R. McClung, "Observations following discontinuation of long-term denosumab therapy", Osteoporosis International, 28(5), pp.1723~1732 (2017), Springer Science and Business Media LLC[DOI]
5. Paul D. Miller, "Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial", Bone, 43(2), pp.222~229 (2008), Elsevier BV[DOI]
6. Albrecht Werner Popp, "Bone mineral density changes after 1 year of denosumab discontinuation in postmenopausal women with long-term denosumab treatment for osteoporosis", Calcified Tissue International, 103(1), pp.50~54 (2018), Springer Science and Business Media LLC[DOI]
7. Anne M. Horne, "Bone Loss After Romosozumab", Denosumab: Effects of Bisphosphonates, 2018, pp.103(1), 55~61[DOI]
8. T. Lehmann, "Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures", Osteoporosis International, 28(10), pp.3067~3068 (2017), Springer Science and Business Media LLC[DOI]
9. Benjamin Z. Leder, "Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up)", Bone, 98, pp.54~58 (2017), Elsevier BV[DOI]
10. Pierre D. Delmas, "Efficacy of Raloxifene on Vertebral Fracture Risk Reduction in Postmenopausal Women with Osteoporosis: Four-Year Results from a Randomized Clinical Trial", The Journal of Clinical Endocrinology & Metabolism, 87(8), pp.3609~3617 (2002), The Endocrine Society[DOI]
11. Eisman JA, "Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis : 2-year results from the DIVA study", J Rheumatol, 35, pp.488~497 (2008)
12. Ourania Nicolatou-Galitis, "Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment", Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 127(2), pp.117~135 (2019), Elsevier BV[DOI]

관련 논문AI추천